Skip to main content

Clarigo update: Get even more accurate NIPT results!

Clarigo has been updated! Clarigo is an innovative non-invasive prenatal test (NIPT) that analyzes cell-free fetal DNA obtained from blood of the mother. This simple, robust and highly reliable test screens for the aneuploidy status of chromosomes 21, 18, and 13 as early as 8 weeks into the pregnancy. The improved accompanying Clarigo Reporter analysis software has a superior accuracy and significantly lower false positive rate. With this updated version of the overall Clarigo v2 workflow, highly accurate gender calling results are generated and a fetal fraction as low as of 3 % is automatically called.

Key-Features
  • Inclusion of Y amplicons in Clarigo reagents for accurate gender calling (optional)
  • Optimized Clarigo Reporter analysis software for accurate fetal fraction determination
  • Automatic calling of samples up to a fetal fraction of 3 % for clear result interpretation
  • High overall call rate
  • Specially designed for implementation in local clinical laboratories using standard lab equipment and Illumina MiSeq, NextSeq, and HiSeq 2500 Next-Generation Sequencing systems
  • Quality Report for more insight to the needs of your laboratory

Interested in finding out more? Download here our brochure!

Ordering information updated Clarigo:

Cat. No. Product Name Genomic target Contents Reactions
MR-2501.096 Clarigo v2 NIPT for chromosomes
13, 18, 21 & optional Gender
1 PCR mix, Taq, AR1 96

Agilent non-invasive prenatal testing (NIPT) products may be subject to certain patents and patent applications owned or licensed by Illumina, Inc. and are sold under a license agreement with Illumina, Inc. Read more here.

For In Vitro Diagnostic Use.